Establishment Labs Holdings Inc. $ESTA Position Boosted by Mudita Advisors LLP

Key Points

• Mudita Advisors LLP increased its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 15.6%, owning 479,359 shares valued at approximately $19.56 million.
• Analysts have mixed opinions on ESTA, with Citigroup and Mizuho raising price targets to $47.00 and $70.00 respectively, while Wall Street Zen downgraded it from a "hold" to a "sell" rating.
• For the latest quarter, Establishment Labs reported an earnings miss with a loss of ($0.57) per share, despite revenue increasing by 16.1% year-over-year to $51.30 million.

Mudita Advisors LLP raised its stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 15.6% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 479,359 shares of the company's stock after buying an additional 64,859 shares during the quarter. Establishment Labs makes up about 9.9% of Mudita Advisors LLP's investment portfolio, making the stock its 4th largest holding. Mudita Advisors LLP owned about 1.66% of Establishment Labs worth $19,560,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in ESTA. Northern Trust Corp lifted its stake in Establishment Labs by 53.9% in the fourth quarter. Northern Trust Corp now owns 28,165 shares of the company's stock valued at $1,298,000 after buying an additional 9,865 shares during the last quarter. LMR Partners LLP lifted its stake in Establishment Labs by 130.4% in the fourth quarter. LMR Partners LLP now owns 23,037 shares of the company's stock valued at $1,061,000 after buying an additional 13,037 shares during the last quarter. Millennium Management LLC lifted its stake in Establishment Labs by 96.9% in the fourth quarter. Millennium Management LLC now owns 711,691 shares of the company's stock valued at $32,788,000 after buying an additional 350,213 shares during the last quarter. Nuveen Asset Management LLC lifted its stake in Establishment Labs by 13.3% in the fourth quarter. Nuveen Asset Management LLC now owns 361,515 shares of the company's stock valued at $16,655,000 after buying an additional 42,413 shares during the last quarter. Finally, Redmile Group LLC lifted its stake in Establishment Labs by 22.3% in the fourth quarter. Redmile Group LLC now owns 320,149 shares of the company's stock valued at $14,749,000 after buying an additional 58,346 shares during the last quarter. 72.91% of the stock is currently owned by institutional investors.

Establishment Labs Price Performance

NASDAQ:ESTA traded up $0.06 during mid-day trading on Monday, reaching $37.53. 74,969 shares of the stock were exchanged, compared to its average volume of 504,616. The business has a fifty day moving average price of $40.85 and a 200 day moving average price of $37.99. The firm has a market capitalization of $1.09 billion, a PE ratio of -12.27 and a beta of 0.85. Establishment Labs Holdings Inc. has a 1-year low of $26.56 and a 1-year high of $50.85. The company has a current ratio of 2.84, a quick ratio of 1.67 and a debt-to-equity ratio of 9.71.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.03). The company had revenue of $51.30 million for the quarter, compared to analyst estimates of $50.80 million. Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.Establishment Labs's quarterly revenue was up 16.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.62) EPS. Establishment Labs has set its FY 2025 guidance at EPS. Research analysts expect that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on ESTA. Needham & Company LLC reiterated a "buy" rating and issued a $48.00 target price on shares of Establishment Labs in a research note on Friday, June 13th. Wall Street Zen cut shares of Establishment Labs from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. Canaccord Genuity Group assumed coverage on shares of Establishment Labs in a research note on Wednesday, August 20th. They set a "buy" rating and a $60.00 price objective on the stock. Citigroup lifted their price objective on shares of Establishment Labs from $38.00 to $47.00 and gave the company a "neutral" rating in a research note on Wednesday, July 9th. Finally, Mizuho lifted their price objective on shares of Establishment Labs from $58.00 to $70.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Establishment Labs currently has an average rating of "Moderate Buy" and an average target price of $56.50.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.